Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics.

Di Ieva A, Magnussen JS, McIntosh J, Mulcahy MJ, Pardey M, Choi C.

World Neurosurg. 2019 Sep 14. pii: S1878-8750(19)32470-2. doi: 10.1016/j.wneu.2019.09.040. [Epub ahead of print]

PMID:
31526886
2.

Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.

Tietze A, Choi C, Mickey B, Maher EA, Parm Ulhøi B, Sangill R, Lassen-Ramshad Y, Lukacova S, Østergaard L, von Oettingen G.

J Neurosurg. 2018 Feb;128(2):391-398. doi: 10.3171/2016.10.JNS161793. Epub 2017 Mar 3.

PMID:
28298040
3.

Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

Choi C, Raisanen JM, Ganji SK, Zhang S, McNeil SS, An Z, Madan A, Hatanpaa KJ, Vemireddy V, Sheppard CA, Oliver D, Hulsey KM, Tiwari V, Mashimo T, Battiste J, Barnett S, Madden CJ, Patel TR, Pan E, Malloy CR, Mickey BE, Bachoo RM, Maher EA.

J Clin Oncol. 2016 Nov 20;34(33):4030-4039. doi: 10.1200/JCO.2016.67.1222. Epub 2016 Oct 31.

4.

Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.

Branzoli F, Di Stefano AL, Capelle L, Ottolenghi C, Valabrègue R, Deelchand DK, Bielle F, Villa C, Baussart B, Lehéricy S, Sanson M, Marjanska M.

Neuro Oncol. 2018 Jun 18;20(7):907-916. doi: 10.1093/neuonc/nox214.

5.

Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.

Alfaro CM, Pirro V, Keating MF, Hattab EM, Cooks RG, Cohen-Gadol AA.

J Neurosurg. 2019 Jan 4:1-8. doi: 10.3171/2018.8.JNS181207. [Epub ahead of print]

PMID:
30611146
6.

In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Cuccarini V, Antelmi L, Pollo B, Paterra R, Calatozzolo C, Nigri A, DiMeco F, Eoli M, Finocchiaro G, Brenna G, Tramacere I, Bruzzone MG, Anghileri E.

Neurol Sci. 2019 Oct 24. doi: 10.1007/s10072-019-04087-9. [Epub ahead of print]

PMID:
31650436
7.

In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.

Kim H, Kim S, Lee HH, Heo H.

Korean J Radiol. 2016 Sep-Oct;17(5):620-32. doi: 10.3348/kjr.2016.17.5.620. Epub 2016 Aug 23. Review.

8.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP.

Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3.

9.

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.

de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB.

Neuro Oncol. 2016 Feb;18(2):283-90. doi: 10.1093/neuonc/nov307. Epub 2015 Dec 20.

10.

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.

Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E.

Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5.

11.

Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.

Natsumeda M, Igarashi H, Nomura T, Ogura R, Tsukamoto Y, Kobayashi T, Aoki H, Okamoto K, Kakita A, Takahashi H, Nakada T, Fujii Y.

Acta Neuropathol Commun. 2014 Nov 7;2:158. doi: 10.1186/s40478-014-0158-y.

12.
13.

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA.

Nat Med. 2012 Jan 26;18(4):624-9. doi: 10.1038/nm.2682.

14.

Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.

Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC.

Neuro Oncol. 2016 Nov;18(11):1569-1578. Epub 2016 Jul 5.

15.

Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

An Z, Tiwari V, Ganji SK, Baxter J, Levy M, Pinho MC, Pan E, Maher EA, Patel TR, Mickey BE, Choi C.

Magn Reson Med. 2018 Apr;79(4):1851-1861. doi: 10.1002/mrm.26884. Epub 2017 Aug 22.

16.

Characterization of IDH1/IDH2 Mutation and D-2-Hydroxyglutarate Oncometabolite Level in Dedifferentiated Chondrosarcoma.

Mohammad N, Wong D, Lum A, Lin J, Ho J, Lee CH, Yip S.

Histopathology. 2019 Oct 14. doi: 10.1111/his.14018. [Epub ahead of print]

PMID:
31609487
17.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

18.

Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.

Lombardi G, Corona G, Bellu L, Della Puppa A, Pambuku A, Fiduccia P, Bertorelle R, Gardiman MP, D'Avella D, Toffoli G, Zagonel V.

Oncologist. 2015 May;20(5):562-7. doi: 10.1634/theoncologist.2014-0266. Epub 2015 Apr 10.

19.

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.

Megova M, Drabek J, Koudelakova V, Trojanec R, Kalita O, Hajduch M.

J Neurosci Res. 2014 Dec;92(12):1611-20. doi: 10.1002/jnr.23456. Epub 2014 Jul 31. Review.

PMID:
25078896
20.

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

Han CH, Batchelor TT.

Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.

Supplemental Content

Support Center